<DOC>
	<DOCNO>NCT01971190</DOCNO>
	<brief_summary>Central serous chorioretinopathy ( CSC ) self-limiting disease usually associate good visual prognosis . In case , however , CSC may persist result permanent retinal retinal pigment epithelium ( RPE ) damage . Therefore , disease persistent beyond acute phase , active treatment consider prevent irreversible damage retinal function . The pathophysiology CSC associate abnormal choroidal circulation . Indocyanine green angiography ( ICGA ) reveal dilate congested choroidal vessel leakage extracellular space appear area hyperfluorescence see middle late phase eye CSC . A goal treatment focus reduce choroidal hyperpermeability . Currently , photodynamic therapy verteporfin ( PDT ) intravitreal anti-VEGF ( vascular endothelial growth factor ) antibody injection try order treat chronic CSC . PDT reduce choroidal hyperpermeability induce hypoperfusion choriocapillaris short term choroidal vascular remodeling time . Intravitreal anti-VEGF injection treatment CSC also effectively reduce choroidal hyperpermeability block vascular leakage . Both method show effective good functional outcome treat chronic CSC many report , establish standard treatment protocol chronic CSC . Bevacizumab ( Avastin ) ranibizumab ( Lucentis ) use widely anti-VEGF therapeutic agent treatment age relate macular generation ( AMD ) macular edema various reason . A newly develop anti-VEGF drug , aflibercept ( Eyleaâ—‹R ) , show high affinity VEGF long duration effect vitreous.FDA approve aflibercept treat wet type AMD macular edema due central retinal vein occlusion . Until , study report efficacy safety aflibercept treat CSC . The aim study evaluate efficacy safety intravitreal aflibercept injection treatment idiopathic CSC</brief_summary>
	<brief_title>Efficacy Safety Intravitreal Aflibercept Injection Subacute Central Serous Chorioretinopathy</brief_title>
	<detailed_description>Single-center Double blind randomized Phase 2 interventional parallel study . Group A : 2mg intravitreal Aflibercept ( Eylea ) injection baseline , 1 month , 2 month Group B : Sham injection baseline , 1 month , 2 month At 3 month , 4 month , 5 month , 6 month , PRN treatment aflibercept injection half-fluence photodynamic therapy may do , one follow condition fulfil . The PRN treatment method decide investigator 's discretion . Of patient persistent intra- subretina fluid SD-OCT 1 . Central subfield thickness decrease 50 micrometer compare baseline central subfield thickness 2 . Best-corrected ETDRS letter score dose increase 5 letter baseline ( persistent CSC ) . 3 . Central subfield thickness thicker previous exam 4 . BCVA letter score worse previous exam ( persistent CSC )</detailed_description>
	<mesh_term>Central Serous Chorioretinopathy</mesh_term>
	<criteria>Clinical diagnosis idiopathic CSC . 18 60 year old , woman man . Subretinal fluid find OCT . Symptom duration 6 week 4 month . Patient agree participate study . Patient treat previously CSC Patient choroidal neovascularization macular disease Patient ophthalmologic disease may affect patient 's vision . History intraocular surgery , except cataract extraction prior 3 month Patient active intraocular inflammation infection Patient uncontrolled glaucoma IOP 25 mmHg spite antiglaucoma medication Visual field defect affect best correct visual acuity Patient use systemic topical carbonic anhydrase inhibitor within 1 month Cushing syndrome History intravitreal steroid injection study eye Patient use plan use systemic drug toxic crystalline lens , retina optic nerve . Patient know allergy fluorescein ICG Pregnant breastfeed woman Patient contraindication aflibercept Ocular periocular infection Active severe intraocular inflammation Known hypersensitivity aflibercept excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>